Overview

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.

Phase:

PHASE2

Details

Lead Sponsor:

L & L Bio Co., Ltd., Ningbo, China

Treatments:

lenvatinib